
Deals & Capital Markets
Royalty Pharma Bets $500M on Teva's Vitiligo Antibody, Targeting Market With Only One Approved Drug
Jan 12
You're signed outSign in or to get full access.
Browse quarterly earnings call transcripts for TEVA PHARMACEUTICAL INDUSTRIES.
Jan 28, 2026
Nov 5, 2025
Jul 30, 2025
May 7, 2025
Jan 29, 2025
Nov 6, 2024
Jul 31, 2024
May 8, 2024
Feb 10, 2021
Nov 5, 2020
Aug 5, 2020
May 7, 2020